The study involved significant activities to estimate the current size of the artificial intelligence (AI) in drug discovery market. Exhaustive secondary research was done to collect information on artificial intelligence (AI) in drug discovery market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the artificial intelligence (AI) in drug doscovery market.
Secondary Research
This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in drug discovery solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.
Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in drug discovery vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies adopted by key players.
After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in drug discovery solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.
In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
Breakdown of the Primary Respondents:
*Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue, as of 2023: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the artificial intelligence (AI) in drug discovery market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
-
The key players in the industry and markets have been identified through extensive secondary research.
-
The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
-
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the artificial intelligence (AI) in drug discovery market.
Market Definition
Artificial intelligence (AI) in drug discovery is the use of Al algorithms and techniques to improve the efficiency and effectiveness of the drug discovery process. Al can be used to automate tasks, analyze large datasets, and generate new insights that would be difficult or impossible to obtain using traditional methods. Al algorithms, particularly machine learning and deep learning models, are employed to analyze vast datasets on genetics, molecular structures, and biological interactions. These Al systems can predict potential drug candidates, assess their safety profiles, and optimize the drug development process.
AI in drug discovery enables faster target identification and in silico drug design. It identifies patterns in data to predict which compounds will be successful medicines. Al is still in the early stages of development in drug discovery, but it has the potential to revolutionize the process by automating tasks and analyzing large datasets. Al can create significant value in drug discovery through three main drivers: time and cost savings, increased probability of success, and novelty of both the molecular target and optimized therapeutic agent.
Stakeholders
-
AI Solution Providers
-
AI Platform Providers
-
Technology Providers
-
AI System Providers
-
Platform Providers
-
System Integrators
-
Pharmaceutical Companies
-
Biotechnology Companies and Start-ups
-
Drug Discovery Ventures
-
Contract Development and Manufacturing Organizations (CDMOs)
-
Contract Research Organizations (CROs)
-
Research Centers and Universities
-
Academic Institutes
-
Forums, Alliances, and Associations
-
Distributors
-
Venture Capitalists
-
Government Organizations
-
Institutional Investors and Investment Banks
-
Investors/Shareholders
-
Consulting Companies in the Drug Discovery Sector and Regulatory Consultants
-
Raw Material and Component Manufacturers
-
Hardware Manufacturers and Suppliers
-
Data Providers
-
Regulatory Agencies
-
Healthcare Providers
-
Patient Advocacy Groups
-
Ethical and Legal Experts
Report Objectives
-
To define, describe, and forecast the global artificial intelligence (AI) in drug discovery market based on by process, use case, therapeutic area, player type, tools, deployment, end user, and region
-
To provide detailed information regarding the factors influencing the growth of the market (such as the drivers, restraints, opportunities, and challenges)
-
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall artificial intelligence (AI) in drug discovery market
-
To analyze market opportunities for stakeholders and provide details of the competitive landscape for market leaders
-
To forecast the size of the artificial intelligence (AI) in drug discovery market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
-
To provide key industry insights such as supply chain analysis, regulatory analysis, patent analysis, and impact of generative AI
-
To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies in the market
-
To track and analyze competitive developments such as product & service launches; expansions; partnerships, agreements, and collaborations; and acquisitions in the artificial intelligence (AI) in drug discovery market
-
To track and analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, agreements, joint ventures, funding, acquisitions, expansions, conferences, FDA clearances, sales contracts, alliances, and R&D activities of the leading players in the market
-
To benchmark players within the artificial intelligence (AI) in drug discovery market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering
Anthony
Jun, 2022
Which market segment is expected to shape the future of the AI in Drug Discovery Market?.
Adam
Jun, 2022
Which are the most innovative companies in AI in Drug Discovery Market?.
Mathew
Jun, 2022
What are the new trends and advancements in the AI in Drug Discovery Market?.